Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop

Yan Liu1,2†, Jian-Xing Wang1,3†, Zi-Yuan Nie4, Yue Wen1, Xin-Ju Jia5, Li-Na Zhang1, Hui-Jun Duan1* and Yong-Hong Shi1*

Abstract

Background: ERp57 dysfunction has been shown to contribute to tumorigenesis in multiple malignances. However, the role of ERp57 in clear cell renal carcinoma (ccRCC) remains unclear.

Methods: Cell proliferation ability was measured by MTT and colony forming assays. Western blotting and quantitative real-time PCR (qRT-PCR) were performed to measure protein and mRNA expression. Co-immunoprecipitation (CoIP) and proximity ligation assay (PLA) were performed to detect protein-protein interaction. Chromatin immunoprecipitation (ChIP), ribonucleoprotein immunoprecipitation (RIP), and oligo pull-down were used to confirm DNA–protein and RNA–protein interactions. Promoter luciferase analysis was used to detect transcription factor activity.

Results: Here we found ERp57 was overexpressed in ccRCC tissues, and the higher levels of ERp57 were correlated with poor survival in patients with ccRCC. In vivo and in vitro experiments showed that ccRCC cell proliferation was enhanced by ERp57 overexpression and inhibited by ERp57 deletion. Importantly, we found ERp57 positively regulated ILF3 expression in ccRCC cells. Mechanically, ERp57 was shown to bind to STAT3 protein and enhance the STAT3-mediated transcriptional activity of ILF3. Furthermore, ILF3 levels were increased in ccRCC tissues and associated with poor prognosis. Interestingly, we revealed that ILF3 could bind to ERp57 and positively regulate its expression by enhancing its mRNA stability. Furthermore, ccRCC cell proliferation was moderated via the ERp57/STAT3/ILF3 feedback loop.

Conclusions: In summary, our results indicate that the ERp57/STAT3/ILF3 feedback loop plays a key role in the oncogenesis of ccRCC and provides a potential therapeutic target for ccRCC treatment.

Keywords: Clear cell renal carcinoma, ERp57, ILF3, STAT3, Proliferation

Background

Kidney cancer is 6th most frequently occurring cancer in men and 9th in women, with 65,340 new cases and 16,970 deaths reported in the United States in 2018 [1]. Clear cell renal cell carcinoma (ccRCC) represents the major subtype of renal cell carcinoma, accounting for 70% of kidney cancers [2]. Early-stage ccRCC patients benefit from the surgery. However, some ccRCC patients are asymptomatic until advanced stages with distant metastases, which have a 5-years survival of less than 20% [3, 4]. As a gene-driven malignancy, many genes have been identified that are involved in the development of ccRCC [5]. However, the basic molecular pathways involved in the development ccRCC remain unclear. Therefore, understanding the molecular mechanisms and identifying therapeutic targets of ccRCC is desirable.

ERp57, also known as GRp58 or PDIA3, is a member of the protein disulfide isomerase (PDI) gene family and is first reported in response to glycoprotein folding in the endoplasmic reticulum (ER) [6, 7]. ERp57 contains extensive functions beyond its abilities in the ER. For example, in the cell membrane, ERp57 acts as a membrane receptor for 1α, 25-dihydroxy-vitamin D3 [8]. In the
cytoplasm, ERp57 co-localizes with NF-κB, ATRA–RARα, and mTOR, forming a complex that has been implicated in various developmental processes [9, 10]. In the nucleus, ERp57 directly interacts with DNA or enhances the DNA-binding of the signal transducer and activator of transcription 3 (STAT3) complex, influencing binding of the transcription factor to DNA, and facilitating nuclear import and export of transcription factor [11]. Therefore, the various subcellular localizations and binding partners of ERp57 affect numerous physiological processes and diseases. A previous study reported that ERp57 is dysregulated in many types of cancer, and upregulation or downregulation of ERp57 is correlated with poor prognosis [12–14]. Interestingly, ERp57 is downregulated in early-stage cervical cancer, whereas it is highly expressed in invasion-stage cervical cancer, suggesting that the role of the ERp57 in cancer is complex and closely related to its molecular partner [9, 15]. However, the expression and function of ERp57 in ccRCC remains unclear.

Interleukin enhancer-binding factor 3 (ILF3) is formed by alternative splicing of the If3 gene and contains double-stranded RNA (dsRNA)-binding motifs (dsRBMs) and a RGG domain that is responsible for its association with AU-rich elements [16]. Previous studies have found that ILF3 was dysregulated in breast tumor, hepatocellular carcinoma, non-small cell lung carcinoma and ovarian cancer [17–20], indicating its potential functions in oncogenesis. For example, ILF3 promotes hepatocellular carcinoma cell proliferation by binding to and stabilizing Cyclin E1 mRNA [18]. ILF3 also moderates RAR1 expression in hepatocellular carcinoma by stabilizing PARP1 mRNA by binding to its 3′ untranslated region (UTR) [21]. Another study also confirmed that ILF3 could bind to VEGF 3′ UTR AREs and enhance mRNA stability in breast cancer [19]. ILF3 was also shown to blocks the microRNA binding site in the urokinase-type plasminogen activator (uPA) 3′ UTR and promote breast cancer cell proliferation [22]. However, whether ILF3 regulates ccRCC proliferation and the underlying molecular mechanism involved remain unclear.

In the present study, we observed increased levels of ERp57 in ccRCC tissue, and higher levels of ERp57 or ILF3 were correlated with poor patient survival. Moreover, overexpression of ERp57 induced ccRCC proliferation in vitro and in vivo. Importantly, we demonstrated protein interaction between ERp57 and STAT3, forming a complex that transcriptionally regulates ILF3 expression. In addition, ILF3 may bind to ERp57 3′ UTR and positively regulate ERp57 expression by enhancing its mRNA stability. Taken together, our results indicate that the ERp57/STAT3/ILF3 feedback loop plays a key role in the proliferation mechanism of ccRCC and provides a potential therapeutic target for ccRCC treatment.

Methods

Tumor tissues and cell lines
ccRCC tissues and pathologically non-tumorous tissue were collected from the ccRCC patients at the Fourth Hospital of Hebei Medical University from July 2016 to June 2017. The protocol of this study was approved by the Ethics Committee of Hebei Medical University and written consent was obtained from each patient. All samples were immediately frozen in liquid nitrogen after surgery and then later stored at −80 °C for further use.

Human ccRCC cell lines (SW839, A498, Caki1, 786–0, OSRC-2 and ACHN) were obtained in our lab. All cell lines were cultured in Dulbecco’s Modified Eagle’s Medium-high glucose (Gibco, USA) containing 10% fetal bovine serum (FBS) at 37 °C in an atmosphere of 5% CO2.

Cell transfection
Lipofectamine 2000 (Invitrogen) was used for cell transfection according to the manufacturer’s protocols. The ERp57-shRNAs, ILF3-shRNAs and shRNA negative controls were designed by GenePharma Co., Ltd. (Shanghai, China). The overexpression plasmids of ILF3, ERp57 and luciferase assay plasmids was purchased from GENEWIZ Company (Suzhou, China).

Quantitative real-time PCR (qRT-PCR)
RNA Purification Kit (RNAeasy Mini Elute kit, QIAGEN) were used to prepare total RNAs from tissues and culture cells according to the manufacturer’s protocol. The concentration and purity of total RNA were measured by using Nanodrop spectrophotometer (Thermo Fisher). M-MLV First Strand Kit (Life Technologies) was used for reversed-transcript the RNA to cDNA. StepOne Plus real-time PCR system (Applied Bioscience) was used for qRT-PCR with the primer as following: ERp57-F:GCAATGATGGGCTGGCTGAG, ERp57-R:TCTTTGCTGAGCTTCTCGCC; β-catenin-F:ATGACTCGAGTCTGCAAGGTT; β-catenin-R:ATTGCAAGTGTGGCAAGTTC; Cyclin E1-F:ATACTT GCTGCTTGGCCCT; Cyclin E1-R:TTGGCAGACTCATCCTGCTT; ILF3-F:CGGAAGTGGGGTATTAGGCTCC; ILF3-R:TGTGGCAGACTCATCCTGCTT; EGFR-F: AACCCCCAGGCAATAACAG; EGFR-R:GGGAGAT CGCCACGTAGGAG; HIF1α-F:ACCTATGACCTGGCTTGGA; HIF1α-R:GGCTGTGTGTCAGTGAGAAA; ILF3-F:TCTCGAGCTCCTCTGCTGTGA; ILF3-R: TCTTCCGGTGGTTCTGCTG; P4HB-F:GCAAAA TCAAGGCCCACTGTT; P4HB-R:ACCATGGGGCATAG AACTCC; Nocth2-F:GGGAAA TCAAGGCCCACTGTT; Nocth2-R:ACCATGGGGCATAG AACTCC; Nocht2-R:ACCATGGGGCATAG AACTCC; PAX3-F: TGCCGTCAGTGGTCTG; PAX3-R:GAAGGG TCAAGGCCCACTGTT; PAX3-R:GAAGGG TCAAGGCCCACTGTT; VDR-F:GCAGTGACCATGAGC GCCGAGC; VDR-R:CGGGAACCCACCCGGGACCTT GAGC TGCAGGCGGAC;}
subjected to quantitative real-time polymerase chain reaction (qRT-PCR) using the Platinum SYBR Green qPCR Super Mix UDG Kit (Invitrogen) and the ABI 7500 FAST system (Life Technologies). All gene-expression levels were normalized to GAPDH and calculated using the 2^{−ΔΔCt} formula.

**Western blot**
Cultured cells and tissues were lysed with RIPA buffer (Beibo, China) and then protein for further western blot following the protocol as describe previously. The antibodies were used in present study as following: anti-ERp57 (Abcam, ab13506), anti-ILF3 (Abcam, ab133354), anti-Cyclin E1 (Abcam, ab33911), anti-Cyclin D1 (Protein-tech, 26,939–1-AP), anti-STAT3 (Abcam, ab68153), anti-pSTAT3 (Abcam, ab76315) and anti-β-actin (Abcam, ab6276).

**Cell proliferation assays**
MTT assay and colony formation assay were used to detect cell viability. For MTT assay, cells were seeded on 96-well plates and then transfected with shERp57 or ERp57 overexpression vector plasmid for 24, 48 or 72 h. 20 μL of MTT reagent (5 mg/mL; Sigma-Aldrich, USA) was added into each well. After incubating for 3–4 h, we measured the absorbance at 495 nm by using a microplate reader (Thermo Fisher, USA). For colony formation assay, 100 cells/well culture cells were seeded into 6-well plates and culture for 1 week and then fixed with a glacial acetic acid/methanol solution. 0.5% crystal violet was used to stain the colonies. Colony numbers was counted under a microscope.

**Proximity ligation assay**
The proximity ligation assay (PLA) was performed as described previously [23]. Briefly, A498 cells were seeded into 6 well chamber slides and cultured for 24 h. Then 4% paraformaldehyde were used to fixate the sliders. Rabbit PLUS and Mouse MINUS Duolink in situ proximity ligation assay (PLA) kits were used to detect the interaction between the two proteins following the manufacturer’s protocols. Fluorescence was detected using a laser scanning confocal microscope.

**Co-immunoprecipitation assay**
Co-immunoprecipitation analysis was performed as described previously. Briefly, cultured cells were lysed by RIPA and then lysates were immunoprecipitated with anti-ERp57 or anti-ILF3 for 1 h at 37 °C. Protein A-agarose were added to the lysates for incubating overnight. Next day, Protein A-agarose-antigen-antibody complexes were collected by centrifugation at 12,000 g for 2 min at 4 °C and immunoprecipitation-HAT buffer was used to washed complexes for 5 times. Western blot was used to detect the bound proteins.

**Biotin pull-down of RNA**
Biotin pull-down analysis was used to detect the interaction between ILF3 protein and ERp57 mRNA as previously described [24]. In brief, cells were transfected with 4 μg biotin-labeled RNA for 24 h. And then cells were cross-linked with 1% formaldehyde in PBS and quenched with 0.125 M glycine. Then cells were resuspended in lysis buffer on ice for 10 min and were sonicated. The cell lysate was diluted in two times volume with hybridization buffer. Streptavidin Dynabeads (Life Technologies) were blocked for 2 h at 4 °C in lysis buffer containing 1 mg/ml yeast tRNA and 1 mg/mL BSA and wash twice with 1 mL lysis buffer. 100 μL washed(blocked Dynabeads was added, and the whole mix was then rotated for 30 min at 37 °C. Beads were captured by magnets (Life Technologies) and washed five times. Beads were then subjected to RNA elution with buffer.

**Animal experiment**
All animal experiment protocol was approved by the Institutional Animal Care and Use Committee of Hebei Medical University (approval ID: HeBMU 20,080,026). 4–6 weeks of BALB/c nude mice were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, china). 5 × 10^6 A498 cells stably knocked down ILF3 and ERp57 or knocked down both of them were mixed with 50% Matrigel matrix then this suspension was injected subcutaneously into the left dorsal flanks of nude mice. The length and width of mouse tumor were measured twice a week with calipers. At the end of the experiment, the mice were euthanized by Carbon dioxide asphyxiation. At last, the tumor tissues were fixed in 4% formalin solution or stored at −80 °C for following experiment.

**Chromatin immunoprecipitation (ChIP) assay**
The chromatin immunoprecipitation (ChIP) assay was performed as described previously [24]. In brief, A498 cells were treated with 1% formaldehyde to cross-link proteins with DNA. The cross-linked chromatin was then prepared and sonicated to an average size of 400–600 bp. The samples were diluted 10-fold and then pre-cleared with protein A-agarose/salmon sperm DNA for 30 min at 4 °C. The DNA fragments were immunoprecipitated overnight at 4 °C with anti-STAT3, anti-ERp57 or anti-IgG (as negative control) antibodies. After cross-linking reversal, ERp57 and STAT3 on ILF3 promoter was examined. Results were determined by qRT-PCR with the following primers: ILF3-chip-F1:GGACAAAGCACTCGGTCACGGG; ILF3-chip-R1:GATGGGAGAACTGAGGCCAGGG; ILF3-chip-F2:GCTTCTTCTTG
were deparaffinized in xylene solution and rehydrated by the ethanol gradient. Five-micrometer paraffin cross-sections of the tissues were then subjected to antigen retrieval with citrate buffer. After hydrogen peroxide and protein blocking, the sections were incubated with primary antibody as following: anti-ILF3 (Abcam, ab13248) and anti-ERp57 (Abcam, ab13506) at 4 °C overnight, and then was incubated in streptavidin (HRP)-biotin labeled secondary antibody. Images were acquired using a Leica microscope (Leica DM6000B, Switzerland) and digitized with LAS V.4.4 (Leica).

RNA immunoprecipitation (RIP) assays
RIP was performed as described previously [23]. In brief, A498 cells were harvested and lysed in NETN buffer and then cells were used to conduct RIP experiments using the anti-ILF3 antibody or IgG, and the Dynabeads™ Protein G Immunoprecipitation Kit (10007D, Thermo Fisher) according to the manufacturer’s instructions. Then the beads were washed three times with NETN buffer and RNA was isolated by using RNA Purification Kit (RNAeasy Mini Elute kit, QIAGEN) according to the manufacturer’s protocol. The RNA fraction isolated by RIP was quantified by NanoDrop 2000 (Thermo-Fisher) and used for RT-qPCR with the following primers:

| Gene    | Forward Primer               | Reverse Primer               |
|---------|------------------------------|------------------------------|
| Cyclin E1-UTR | E-UTR-F:AGCGCTGTTTTGCTTTTACAGA | E-UTR-R:AGCACCCTTCCATTAGCAGCAT |
| ERp57-UTR | F:GGGCGAGAGGACGAGATGTTG | R:GGTGGGAGAAGGAAGGAGG |
| Cyclin D1-UTR | F:AGGGCGAATTCACACAG | R:GTCCGACTTCAGCAGGG |
| GAPDH-F | ATGAAATGCGGAGCGTTAGG | GAPDH-R:TCATCCTGGCAATGTGAGAA |
| Cyclin E1-UTR | F:CAGACCTTCCATAGCAGCAT | R:GGTGGGAGAAGGAAGGAGG |
| ERp57-UTR | F:GGGCGAGAGGACGAGATGTTG | R:GGTGGGAGAAGGAAGGAGG |

 Luciferase assay
Luciferase assay analysis was performed as described previously [24]. In brief, A498 cells were seeded into a 24-well plate, ILF3 reporter construct or the empty reporter vector was co-transfected with pWPI-STAT3 and pRL-TK, or co-transfected with pWPI-vector and pRL-TK. After 24 h of transfection, luciferase activity was measured using a Dual-Glo Luciferase Assay System (Promega, Madison, WI) with a Flash and Glow (LB955, Berthold Technologies) reader. The specific target activity was expressed as the relative activity ratio of firefly luciferase to Renilla luciferase.

Immunofluorescence staining
Cells were fixed with 4% formaldehyde and pre-incubated with 10% normal goat serum (710,027, KPL, USA). Following incubating with primary antibodies anti-ILF3 (Abcam, ab89100) and anti-ERp57 (Abcam, ab13248) and fluorescent-labeled secondary antibodies, then DAPI (157,574, MB biomedical) was used to stain nuclear counter. Images were captured by confocal microscopy (DM6000 CFS, Leica) and processed by LAS AF software.

Immunohistochemistry (IHC) analysis
Five-micrometer paraffin cross-sections of the tissues were deparaffinized in xylene solution and rehydrated by using gradient ethanol concentrations. Sections were subjected to antigen retrieval with citrate buffer. After hydrogen peroxide and protein blocking, the sections were incubated with primary antibody as following: anti-ERp57 (Abcam, ab13506) and anti-ILF3 (Abcam, ab13248) at 4 °C overnight, and then was incubated in streptavidin (HRP)-biotin labeled secondary antibody. Images were acquired using a Leica microscope (Leica DM6000B, Switzerland) and digitized with LAS V.4.4 (Leica).

Statistical analysis
Data were presented as mean ± SEM. Student’s t test was used to analyze differences between two groups. Spearman’s correlation analysis was used to evaluate the correlation analysis. Values of P < 0.05 were considered statistically significant. Graphpad Prism 7.0 software was used to perform the statistical analysis (GraphPad Software, San Diego, CA, USA).

Results
ERp57 is upregulated in ccRCC tissues and contributes to poor prognosis
To identify the expression levels of ERp57 in ccRCC, we first measured its level in 35 samples of ccRCC tissues by qRT-PCR and Western blot analysis. The results showed that both mRNA and protein levels of ERp57 were frequently increased in ccRCC tissues (T) compared to normal kidney tissues (T) in a cohort of ccRCC specimens by immunohistochemistry staining using an ERp57-specific antibody (Fig. 1c). In order to investigate the clinical significance of ERp57 in ccRCC, we analyzed the ERp57 mRNA expression level in 35 ccRCC and their clinicopathologic characteristics. The correlation analysis of ERp57 mRNA level significantly associated tumor size and overall survival (Fig. 1e). These results suggest that the upregulation of ERp57 promotes ccRCC progression.

ERp57 plays a critical role in ccRCC cell proliferation and migration
Previous studies have indicated that ERp57 may function as an oncogene to promote the progression of multiple cancers [25, 26]. To investigate the biological functions of ERp57 in ccRCC cell survival, some in vitro loss and gain-of-function experiments were performed. First, we detected relative ERp57 mRNA expression levels in six different ccRCC cell lines (Fig. 2a). qRT-PCR analysis showed that the A498 cell line expressed the lowest...
levels of ERp57 mRNA compared with the other ccRCC cell lines; therefore, this cell line was selected for gain-of-function experiments. Higher levels of ERp57 mRNA expression were observed in the SW839 cell line; therefore, this cell line was selected for loss-of-function experiments. Next, we knocked down ERp57 in SW839 cells using specific shRNA and overexpressed ERp57 in A498 cells by transfecting cells with a pWPI–ERp57 overexpression vector. Western blotting results showed that transfection of shERp57 led to significantly downregulated levels of ERp57 and the proliferation maker gene, Cyclin E1, in A498 cells compared with the shRNA control vector, while transfection of pWPI–ERp57 in SW839 cells led to upregulated ERp57 and Cyclin E1 protein levels compared with empty vector (Fig. 2b). MTT analysis showed that overexpression of ERp57 promoted A498 cell growth, while suppression of ERp57 inhibited cell proliferation in SW839 cells (Fig. 2c). Colony formation analysis further confirmed these results (Fig. 2d). In addition, transwell migration assay showed that overexpression of ERp57 induced A498 cell migration. Consistently, knockdown of ERp57 in SW839 cells led to markedly reduced cell migration ability (Fig. 2e). Together, these findings suggest that ERp57 functions to promote proliferation and migration in ccRCC cells.

ILF3 is positively regulated by ERp57
To further demonstrate how ERp57 regulates proliferation of ccRCC cells, we selected genes previously reported to be regulated by ERp57 and partially related to cell proliferation. We measured mRNA levels of 11 candidate genes by real-time PCR in the SW839 and A498 cell lines. As shown in Fig. 3a, ILF3 was the only gene that was significantly downregulated in ERp57-depleted SW839 cells, while ILF3 was upregulated in ERp57-overexpressing A498 cells. Western blot analysis showed that overexpression of ERp57 increased ILF3 protein levels; whereas knockdown of ERp57 decreased ILF3
protein levels in ccRCC cells (Fig. 3b). ILF3 expression levels were then measured in ccRCC tissues. The qRT-PCR results showed that ILF3 mRNA levels were significantly higher in ccRCC tissue compared with normal kidney tissues (Fig. 3c). These results were consistent with those found in the TCGA database (Fig. 3d). Additionally, western blot analysis and immunohistochemistry analysis showed that ccRCC tissues had higher protein levels of ILF3 compared with normal kidney tissues (Fig. 3e and f). Additionally, we analyzed the clinical significance of ILF3 in ccRCC, and found that ILF3 mRNA level significantly associated tumor size (Table 1).

Survival analysis from the TCGA database showed that higher expression of ILF3 was associated with poor prognosis (Fig. 3g). Therefore, we analyzed the correlation between ERp57 and ILF3 mRNA in ccRCC cells. We found that suppression of STAT3 expression decreased ILF3 mRNA levels, while enhanced STAT3 expression increased ILF3 mRNA levels in ccRCC cells (Fig. 4a). Rescue experiments further demonstrated that STAT3 mediates the relationship between ERp57 and ILF3. Co-transfection of SW839 cells with shSTAT3 and shERp57 significantly enhanced the inhibitory effects on ILF3 and Cyclin E1 compared with knockdown of STAT3 alone. In contrast, transfection of A498 cells with shSTAT3 reduced ILF3 and Cyclin E1 levels, while this reduction effect could be reversed by co-transfection with ERp57 overexpression vector. Furthermore, as Fig. 4c showed, depletion of STAT3 or ERp57 alone suppressed cell proliferation by using BrdU immunohistochemistry. And these suppression effects could strengthen by knocking down STAT3 and ERp57 together. We next investigated whether ERp57 functioned as a protein partner of STAT3. As expected, co-immunoprecipitation (CoIP) and PLA results confirmed protein–protein interactions between STAT3 and ERp57 (Fig. 4d and f). To further demonstrate the involvement of ERp57 binding with STAT3 in ILF3 transcription, we predicted the putative binding

### Table 1 Clinicopathological Characteristics

| Characteristics | ERp57 expression | ILF3 expression |
|-----------------|------------------|----------------|
|                 | Low (%)  | High (%)  | P value | Low (%)  | High (%)  | P value |
| Age             |         |          |         |        |          |        |
| ≤ 56 years      | 9 (50.00) | 9 (50.00) | 0.738   | 8 (42.11) | 11 (57.89) | 0.505   |
| > 56 years      | 7 (41.18) | 10 (58.82) |            | 9 (56.25) | 7 (43.75) |           |
| Gender          |         |          |         |        |          |        |
| Male            | 11 (45.83) | 13 (54.17) | 1.000   | 9 (39.13) | 14 (60.87) | 0.164   |
| Female          | 5 (45.45) | 6 (54.55) |            | 8 (66.67) | 4 (33.33) |           |
| Tumor size      |         |          |         |        |          |        |
| ≤ 7 cm          | 8 (80.00) | 2 (20.00) | 0.022   | 10 (76.92) | 3 (23.08) | 0.015   |
| > 7 cm          | 8 (32.00) | 17 (68.00) |            | 7 (31.82) | 15 (68.18) |           |
| pT status       |         |          |         |        |          |        |
| pT1 - pT2       | 7 (41.18) | 10 (58.82) | 0.738   | 9 (45.00) | 11 (55.00) | 0.738   |
| pT3 - pT4       | 9 (50.00) | 9 (50.00) |            | 8 (53.33) | 7 (46.67) |           |
| pN status       |         |          |         |        |          |        |
| pN0             | 12 (52.17) | 11 (47.83) | 0.476   | 8 (38.10) | 13 (61.90) | 0.176   |
| pN1 – pN3       | 4 (33.33) | 8 (66.67) |            | 9 (64.29) | 5 (35.71) |           |
| TNM stage       |         |          |         |        |          |        |
| I-II            | 9 (42.86) | 12 (57.14) | 0.739   | 10 (52.63) | 9 (47.37) | 0.738   |
| III-IV          | 7 (50.00) | 7 (50.00) |            | 7 (43.75) | 9 (56.25) |           |

STAT3 mediates the ERp57 regulating ILF3

A previous study reported that ERp57 functions as a chaperone protein involved in transcription factor activity. Several studies have indicated that ERp57 binds to STAT3 to form an ERp57/STAT3 complex. This complex is required for the transcriptional activity of STAT3 and some genes downstream of STAT3 [27, 28]. Therefore, we investigated whether STAT3 acted to mediate ERp57 and ILF3. To test this, we first investigated whether STAT3 regulated ILF3 expression in ccRCC cells. We found that suppression of STAT3 expression decreased ILF3 mRNA levels, while enhanced STAT3 expression increased ILF3 mRNA levels in ccRCC cells (Fig. 4a). Rescue experiments further demonstrated that STAT3 mediates the relationship between ERp57 and ILF3. Co-transfection of SW839 cells with shSTAT3 and shERp57 significantly enhanced the inhibitory effects on ILF3 and Cyclin E1 compared with knockdown of STAT3 alone. In contrast, transfection of A498 cells with shSTAT3 reduced ILF3 and Cyclin E1 levels, while this reduction effect could be reversed by co-transfection with ERp57 overexpression vector. Furthermore, as Fig. 4c showed, depletion of STAT3 or ERp57 alone suppressed cell proliferation by using BrdU immunohistochemistry. And these suppression effects could strengthen by knocking down STAT3 and ERp57 together. We next investigated whether ERp57 functioned as a protein partner of STAT3. As expected, co-immunoprecipitation (CoIP) and PLA results confirmed protein–protein interactions between STAT3 and ERp57 (Fig. 4d and f). To further demonstrate the involvement of ERp57 binding with STAT3 in ILF3 transcription, we predicted the putative binding
sites of STAT3 in ILF3 promotor fragment. ChIP qPCR analysis and luciferase reporter assays were used to show that STAT3 regulates ILF3 transcription. As shown in Fig. 4g, the ILF3 promoter contains three different sequences that could act as binding sites for STAT3. ChIP PCR results showed both STAT3 and ERp57 proteins could bind to sites 1 and 2, but not site 3. Meanwhile, we performed luciferase reporter assays to determine whether ERp57 combined with STAT3 could promote ILF3 transcription. We found that overexpression of ERp57 markedly increased the activity of the luciferase vector present in the ILF3 promoter. However, luciferase activity remained unchanged after knockdown of endogenous STAT3 combined with transfection of ERp57 overexpression vector (Fig. 4h), suggesting that STAT3 directly cross-linked with the ILF3 promotor. These results indicate that ERp57 interacts with STAT3 and promotes the transcription factor activity of STAT3.

ILF3 regulates ERp57 by promoting ERp57 mRNA stability
Since ERp57 and ILF3 were positively correlated in ccRCC and ERp57 moderated ILF3 expression, we investigated whether ILF3 regulates ERp57 expression in ccRCC. Surprisingly, overexpression of ILF3 promoted ERp57 mRNA levels, while knockdown of ILF3 inhibited ERp57 mRNA level in ccRCC cells (Fig. 5a). As an RNA-binding protein, ILF3 has been reported to bind to the Cyclin E1 3′UTR, leading to mRNA stabilization. Therefore, we explored whether ILF3 could bind to ERp57 mRNA and moderate its stability. We used qRT-PCR analysis to measure changes in ERp57 mRNA levels over time after blocking transcription with Actinomycin D (ActD). We found that depletion of ILF3 in SW839 cells inhibited the effects of ActD on ERp57 mRNA stability, whereas ILF3 overexpression promoted the effects of ActD, indicating that ILF3 promoted ERp57 expression by enhancing its mRNA stability (Fig. 5b). To further
explore this, we investigated whether ILF3 could bind to the ERp57 mRNA 3′UTR. We performed an in vitro RNA pull-down assay and a RNA immunoprecipitation assay (RIP). The CoIP results showed that the ILF3 antibody could pull down sufficient levels of endogenous ILF3 protein (Fig. 5c). RIP-PCR analysis showed that Cyclin E1 and ERp57 mRNA 3′UTR, but not Cyclin D1, were present in the protein–RNA complex pulled down by the ILF3 antibody (Fig. 5d and e). Consistently, biotin oligo pull-down also revealed that precipitates from the ERp57 mRNA-3′UTR and positive control Cyclin E1-mRNA probes contained ILF3 protein, but the Cyclin
**Fig. 4** STAT3 mediates the ERp57 regulating ILF3.  

a. SW839 cells were transfected shSTAT3 or A498 were cells transfected with STAT3 overexpression vector pWP-STAT3. ILF3 mRNA level was measured by qRT-PCR. *P < 0.05, **P < 0.01 vs. corresponding control.  

b. SW839 cells were transfected shSTAT3 or shERp57 respectively or co-transfected them together. A498 cells were transfected with shSTAT3 or pWP-ERp57 respectively or co-transfected them together. qRT-PCR detected ILF3 mRNA level. *P < 0.05 vs. corresponding control. Western blot performed to detect ERp57, STAT3, ILF3 and Cyclin E1 protein level.  

c. SW839 cells were transfected shSTAT3 and shERp57 respectively or transfected them together. Cell proliferation was measured by BrdU stain. Scale bar = 20 μm. Right panel showed analysis for BrdU positive cell number. *P < 0.05 vs corresponding control.  

d. A498 cells were transfected with pWP-ERp57 or empty vector and then cell lysates were immunoprecipitated with antibody against ERp57. Western blot detected ERp57 and STAT3 protein level in lysates.  

e. A498 were treated as (d). PLA analysis was used to test the interaction between ERp57 and STAT3. Analysis of number of PLA positive cells. *P < 0.05 vs. empty vector.  

f. Potential binding site of STAT3 in ILF3 promotor. ChIP-qPCR was used to test STAT3 and ERp57 binding to the ILF3 promotor region in 293A cells. *P < 0.05, **P < 0.01 vs. IgG.  

g. ILF3 promoter-luciferase reporter were co-transfected with pWP-ERp57 or co-transfected pWP-ERp57 combination of shSTAT3 vector into 293A cells, and then luciferase reporter assays were performed. *P < 0.05 vs. corresponding control.
Fig. 5 (See legend on next page.)
Intervention of ILF3/ERp57/STAT3 axis inhibits ccRCC xenograft growth in vivo

We used a ccRCC nude mouse xenograft model to corroborate our findings that ERp57 and ILF3 were involved in ccRCC cell growth in an in vivo model. To test this, SW839 cells with stably depleted ERp57 or ILF3 alone, or knockdown of both were implanted into nude mice. As expected, tumor volumes were significantly decreased in the shERp57 and shILF3 groups compared with vehicle control group. Furthermore, the tumor volume was much smaller in mice implanted with cells with simultaneous knockdown of ERp57 and ILF3 compared with those with depletion of either ERp57 or ILF3 alone (Figs. 7a and b). Consistent with these findings, the mean wet weights of the tumors were significantly lower in mice with combined knockdown of ERp57 and ILF3 compared with those with knockdown of either ERp57 or ILF3 alone (Fig. 7c). Western blot analysis demonstrated that silencing of either ERp57 or ILF3 alone significantly downregulated levels of p-STAT3, ERp57, ILF3, and Cyclin E1, and was accompanied by an increase in cleaved caspase-3 expression compared with vehicle control. These effects could be enhanced by combined knockdown of ERp57 and ILF3 (Fig. 7d). TUNEL staining was used to measure cell apoptosis in xenograft tumors and showed that depletion of either ERp57 or ILF3 promoted apoptosis and was enhanced by combined suppression of ERp57 and ILF3 (Fig. 7e). Furthermore, depletion of ERp57 or ILF3 could decreased the number BrdU positive cell while these effects cloud be enhanced by knocking down them together, indicating that downregulated ERp57 or ILF3 inhibited cell proliferation in vivo (Fig. 7f). As shown in Additional file 1: Figure S1 A, SW839 cells with stably depleted shSTAT3 were implanted into nude mice. The tumor volumes were significantly decreased in the shSTAT3 groups compared with vehicle control group, indicating that knockdown of shSTAT3 inhibited ccRCC cell growth in vivo. As shown in Additional file 1: Figure S1, SW839 cells with stably depleted shSTAT3 were implanted into nude mice. The tumor volumes were significantly decreased in the shSTAT3 groups compared with vehicle control group, indicating that knockdown of shSTAT3 inhibited ccRCC cell growth in vivo. These data also suggested that ILF3 and ERp57 regulate ccRCC cell proliferation.
**Fig. 6** (See legend on next page.)

### A

|          | pLKO | shILF3 | Niclosamide  |
|----------|------|--------|-------------|
| STAT3    | +    | −      | +           |
| p-STAT3  | −    | +      | −           |
| Cyclin E1| +    | −      | +           |
| ILF3     | −    | +      | −           |
| β-actin  | +    | −      | −           |

### B

|          | DAPI | Anti-BrdU | Merge |
|----------|------|-----------|-------|
| pLKO     |      |           |       |
| shILF3   |      |           |       |
| + Niclosamide | | | |
| Vehicle  |      |           |       |

### C

|          | shSTAT3 | shERp57 |
|----------|---------|---------|
| SW839    | −       | +       |
| shSTAT3  | −       | +       |
| oeERp57  | −       | −       |

### D

|          | pLKO | shILF3 |
|----------|------|--------|
| TUNEL    |      |        |
| Merge    |      |        |
| pLKO     |      |        |
| shERp57  |      |        |

*Note: *Details of the legend are to be found on the next page.*
proliferation. Figure 8 shows our proposed model illustrating the role of the ERp57/STAT3/ILF3 feedback loop in ccRCC.

**Discussion**

In present study, we reported an investigation of biological role of ERp57/STAT3/ILF3 feedback loop in the moderation of ccRCC oncogenesis. First, ERp57 expression was found to be significantly increased in ccRCC tissues in the TCGA database and in clinical samples, and higher levels of ERp57 in patients were correlated with poor prognosis. Second, ERp57 was shown to function as an oncogene, promoting ccRCC proliferation and migration in vivo and in vitro. Third, ERp57 positively regulated ILF3 expression. Mechanically, ERp57 binds to STAT3, which acts as an ILF3 transcription factor to form a stable complex that can activate downstream transcription factors. Additionally, ILF3 may could enhance ERp57 mRNA stability by binding to ERp57 mRNA, suggesting that ERp57/STAT3/ILF3 plays a growth promotion in ccRCC.

ERp57 is a key member of the PDI family. Similar to disulfide isomerase, ERp57 is localized in the ER and plays a direct role in protein folding and an indirect role in major histocompatibility complex heavy chain loading [29, 30]. However, unlike traditional PDI family members that are only localized in ER, ERp57 was also found in various other subcellular locations, such as the cytosol, mitochondria, and the membrane [31–34]. Due to the characteristics of its localization, ERp57 plays a critical role in binding proteins to mediate the signaling pathway activation [35]. There is growing evidence to show dysregulation of ERp57 in various malignant cells including ovarian cancer [12], breast cancer [36], melanoma [34], laryngeal cancer [27] and leukemia [37]. For example, depletion of ERp57 in breast cancer cell reduces cell proliferation by regulating PERK-mediated activation of the unfolded protein response [25]. Moreover, ERp57 affects mTORC1 activation by interacting with mTOR, and is associated with cell proliferation [38]. In the present study, we first confirmed significantly higher levels of ERp57 in ccRCC tissue compared with normal kidney tissue. We further analyzed the relationship between ERp57 levels and patient outcome and found that higher levels of ERp57 in ccRCC patients were associated with poor prognosis. Our screening identified that knockdown of ERp57 inhibited cell proliferation of ccRCC in vivo and in vitro, indicating that ERp57 plays a role in the promotion of ccRCC cell proliferation.

Signal transducer and activator of transcription 3 (STAT3) is a member of STAT family that regulates the transcription of responsive genes involved in a variety of critical functions, including cell differentiation, proliferation, apoptosis and angiogenesis [39, 40]. There is abundant evidence to show that elevated levels or abnormal activation of STAT3 contribute to cancer cell proliferation, including breast cancer [41], prostate cancer [42], colon cancer [43], and leukemia [44]. Qin showed that p-STAT3 was overexpressed in patients with ccRCC, and high expression of nuclear p-STAT3 was associated with poor patient survival. Moreover, increased expression of pSTAT3 was also shown to be correlated with poor tumor features, such as high tumor grade, large tumor size, and advanced T stage and AJCC stage [45]. However, STAT3 does not act alone, and co-activators such as CBP/p300, c-jun, Oct-1, and NcoA/SRC1a have been confirmed to be associated with this transcriptional factor [46–48]. Studies have demonstrated that ERp57 could bind to STAT3 in the cytoplasm and facilitate STAT3 shuttling cytosol to the nucleus [49, 50]. In addition, nuclear ERp57 functions as a chaperone that binds to DNA and enhances DNA-binding of the STAT3 complex to activate proximal transcription factors [51]. In the present study, we revealed that ERp57 could interact with STAT3 and form a complex. The complex simultaneously cross-linked to the ILF3 DNA promoter and enhanced ILF3 transcription. Importantly, we confirmed that ERp57 is essential for STAT3 transcriptional activation of ILF3. Further studies are required to determine whether ERp57 plays a role in STAT3 transportation from the cytoplasm to the nucleus.

STAT3 regulates various target genes that have different effects on tumorigenesis. Several recent studies have shown that STAT3 transcriptionally regulates key tumor-driving genes that are essential for tumor pathogenesis, such as TNFRSF1A [52], MCY and SOX1 [53]. In addition, STAT3 may interact with the non-coding
RAN promoter to facilitate its transcription [54]. In the present study, we revealed that STAT3 directly promoted ILF3 gene as a transcription factor, and that ILF3 levels were dependent on STAT3 activation. Both shRNA-mediated depletion of STAT3 and reduction of p-STAT3 via a molecular inhibitor decreased ILF3 levels in ccRCC cells. Furthermore, STAT3 regulation of ILF3 was involved in ccRCC proliferation. Importantly, we
found that niclosamide could reduce ccRCC cell growth in vitro by targeting the STAT3/ILF3 axis, indicating its antitumor effect in ccRCC. However, further in vivo experiments and clinical trials are required to confirm its effects in the clinical treatment of ccRCC.

ILF3, also as known as NF90, NF110, and CBTF in humans, is an important double-stranded RNA-binding protein generated via splicing of the ILF3 gene [55]. By binding to various RNAs, ILF3 is considered to be involved in almost all steps of RNA metabolism, from transcription to degradation. For example, as a transcription factor co-activator, ILF3 together with NF45 binds to a CTGTT sequence and promotes human breast tumor progression by regulating uPA expression [19]. ILF3 interacts with the transcription factor, p54, to assist p54-mediated promotion of the human survivin gene expression that plays a key role in tumor proliferation and apoptosis [56]. As a translational regulator, ILF3 is involved in retaining cellular transcripts in the nucleus and controlling their export into the cytoplasm and promotes protein translation [57]. As a promoter of mRNA stabilization, ILF3 may bind to the AG-rich element of a gene’s 3’ UTR to enhance mRNA stability [58]. On the other hand, ILF3 blocks the binding site of degradation factors to prevent mRNA degradation, leading to mRNA stabilization [59]. In the present study, we first confirmed that ILF3 positively regulated Erp57 expression. We first demonstrated that ILF3 acted as an RNA-binding protein and could bind to the Erp57 mRNA 3’ UTR to stabilize Erp57 mRNA. This demonstrated that ILF3/Erp57 formed a positive feedback loop mediating STAT3, and ILF3/STAT3/Erp57 together promoted ccRCC proliferation. Analysis of clinical samples and the TCGA database showed that higher ILF3 levels in patients was correlated with poor survival, indicating that ILF3 may function as a clinical biomarker of prognosis. However, studies using larger numbers of clinical samples are required to further evaluate its clinical value.

Importantly, we revealed a feedback loop regulation which involved in ccRCC proliferation in the present study. In general, Erp57 as a protein partner, interacts with STAT3, forming a complex which transcriptionally regulates ILF3 expression. In contrast, ILF3 binds to Erp57 3’UTR and positively regulate Erp57 expression by enhancing its mRNA stability. The mutual promotion effect of Erp57 and ILF3 participates in ccRCC progression.

**Conclusion**

In summary, the present study demonstrated that dysregulation of Erp57 enhanced ccRCC cell survival by initiating a STAT3/ILF3 feedback loop that was correlated with prognosis in patients with ccRCC. These findings provide useful insight into the regulation of tumor cell metabolism by Erp57/STAT3/ILF3 in ccRCC as a potential therapeutic target.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13046-019-1453-z.

**Additional file 1: Figure S1.** SW839 cells engineered to stably knockdown of STAT3 then the cells were injected subcutaneously to the nude mice to establish ccRCC xenograft tumors. Tumor volumes were monitored by direct measurement.

**Abbreviations**

cCRCC: Clear cell renal cell carcinoma; ChIP: Chromatin immunoprecipitation; CoIP: Co-immunoprecipitation; IFN3: Interleukin enhancer-binding factor 3; PDI: Protein disulfide isomerase; PLA: proximity ligation assay; RIP: RNA
immunoprecipitation; STAT3: Signal transducer and activator of transcription 3; TCGA: The Cancer Genome Atlas; uPA: urokinase-type plasminogen activator; UTR: untranslated region

Acknowledgements
Not available.

Authors' contributions
Conception and design: HD, YS and YL; Development of methodology: JW, YL, ZN and OY; Acquisition of the data: YL, JW and XJ; Analysis of data: ZN, XJ and YL; Writing the manuscript: ZN, YL and HD. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
The present study was authorized Ethics Committee Hebei Medical University. All patients and volunteers were anonymous and provided written informed consent.

Consent for publication
Written consent was obtained from all participants.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Pathology, Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang 050017, People's Republic of China. 2Department of Anesthesiology, The 4th Hospital of Hebei Medical University, 169 Tianzhan Street, 050000, Shijiazhuang, People's Republic of China. 3Department of Otolaryngology, The Second Hospital of Hebei Medical University, 215 Heping West Road Shijiazhuang, 050000 Shijiazhuang, People's Republic of China. 4Department of Hematology, The Second Hospital of Hebei Medical University, 215 Heping West Road Shijiazhuang, 050000 Shijiazhuang, People's Republic of China. 5Department of Endocrinology, The Second Hospital of Hebei Medical University, 215 Donggang Road Shijiazhuang, 050000 Shijiazhuang, People's Republic of China.

Received: 28 July 2019 Accepted: 16 October 2019
Published online: 30 October 2019

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373(9669):1119–32.
3. Belsante M, Danwich O, Youssif R, Bagrodia A, Kapur P, Sagalowsky AI, Lotan Y, Margulis V. Lymphovascular invasion in clear cell renal cell carcinoma—association with disease-free and cancer-specific survival. Urol Oncol. 2014;32(1):30.e23–38.
4. Piccinni S, Guille F, Schips L, de la Taille A, Prayer Galetti T, Tostain J, Cindolo L, Novara G, Zigeuner R, Bratti E, et al. Proposal for revision of the TMA classification system for renal cell carcinoma. Cancer. 2005;104(10):2116–23.
5. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7465):43–9.
6. Shishkin SS, Eremina LS, Kovalev MA. AGR2, ERp57/GRP58, and some other human protein disulfide isomerases. Biochemistry (Mosc). 2013;78(13):1415–30.
7. Ellgaard L, Frideel EM, Calnexin, calreticulin, and ERp57: teammates in glycoprotein folding. Cell Biochem Biophys. 2003;39(3):223–47.
8. Sequeira VB, Rybchyn MS, Tongkao-On W, Gordon-Thomson C, Malloy PJ, Nernier E, Norman AW, Reive VE, Halliday GM, Feldman D, et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1alpha,25-dihydroxyvitamin D3. Mol Endocrinol. 2012;26(4):574–82.
9. Zhu L, Santos NC, Kim KH. Disulfide isomerase glucose-regulated protein 58 is required for the nuclear localization and degradation of retinoic acid receptor alpha. Reproduction. 2010;139(4):717–31.
10. Wu W, Beilhartz G, Roy Y, Richard CL, Curtin M, Brown L, Cadieux D, Coppolino M, Farah-Charon MC, Nemere I, et al. Nuclear translation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NF-kappaB in differentiating NB4 leukemia cells. Exp Cell Res. 2010;316(7):1101–8.
11. Coe H, Jung J, Groenendyk J, Prins D, Michalak M. Erp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum. J Biol Chem. 2010;285(9):6725–38.
12. Zhu Y, Cai LQ, Guo J, Chen N, Yi XQ, Zhao Y, Cai J, Wang ZH. Depletion of dior promotes epithelial ovarian cancer progression by elevating PDIA3 expression. Tumor Biol. 2016;37(10):14009–23.
13. Wise R, Duhachek-Muggly S, Q Y, Zolkiewski M, Zolkiewska A. Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells. Breast Cancer Res Tr. 2016;15(2):241–52.
14. Cicchillitti L, Di Michele M, Urbani A, Ferlini C, Donati MB, Scambia G, Rotilio G. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian Cancer cell line and its resistant counterpart A2780T1 by 2-D DIGE: the role of Erp57. J Proteome Res. 2009;8(4):1902–12.
15. Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, Tsai MM, Lai CH, Liang Y, Jung SM, Lin KH. Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci; 2011;102(1):2255–63.
16. Larcher JC, Garsin L, Vranaincken W, Edde B, Bernard R, Giraborg I, Denoulet P, Ifis and NF90 associate with the axonal targeting element of tau mRNA. FASEB J. 2004;18(14):1761–3.
17. Cheng CC, Chou KF, Wu CW, Su NW, Peng CL, Su YW, Chang J, Ho AS, Lin HC, Chen CG, et al. EGFR-mediated interleukin enhancer-binding factor 3 contribute to formation and survival of cancer stem-like tumours as a therapeutic target against EGFR-positive non-small cell lung cancer. Lung Cancer. 2018;116:80–9.
18. Wang H, Huang H, Ding L, Zhu P, Sayin H, Ji G, Zou J, Han D, Pan Y, Ding D, et al. Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 2013;34(34):4460–70.
19. Hu Q, Lu YY, Noh H, Hong S, Dong Z, Ding HF, Su SB, Huang S. Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene. 2013;32(34):3933–43.
20. Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petrov WS, Mueller MD, Yu J. Correlations among ERCC1, XPR1, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Rep. 2011;27(1):286–92.
21. Shin J, Lim H, J RY, Karin M. Nuclear export of NF90 is required for interleukin-2 mRNA stabilization. Mol Cell 2002, 10(6):1331–1344.
22. Zhang C, Yang C, Zhang M, Li H, Gong C, Zhang J, Xu S, Zou J, Kai Y, Li Y. Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration. Oncotarget. 2017;8(64):107477–91.
23. Sun Y, Yang Z, Zheng B, Zhang XL, Zhao XS, Zhao HY, Suzuki T, Wen JK. A novel regulatory mechanism of smooth muscle alpha-actin expression by NRG-1/circACTA2/mir-548-Fp Sp Axis. Circ Res. 2017;121(6):628–35.
24. Yang Z, Qu CB, Zhang Y, Wang WF, Dang D, Gao CC, Ma L, Chen JS, Liu KL, Zheng B, et al. Dysregulation of p53-IRBP25-mediated circAMOTL1 biogenesis contributes to prostate cancer progression through the circAMOTL1-mir-193a-3p-Podha pathway. Oncogene. 2019;38(14):2516–32.
25. HUSSMANN M, JANKE K, KRASZ P, NEUMANN F, MERICH E, BAUMANN M, GOEPFEL X, BROMDIEGER U, METZEN E. Depletion of the thiol oxidoreductase ERp57 in tumor cells inhibits proliferation and increases sensitivity to ionizing radiation and chemotherapeutics. Oncotarget. 2015;6(36):39247–61.
26. Guacci E, Altieri F, Turano C, Chichiarelli S. The protein Erp57 contributes to EGF receptor signaling and internalization in MDA-MB-488 breast cancer cells. J Cell Biochem. 2013;114(11):2461–70.
27. CHOE MH, MIN JW, JEON HB, CHO OH, OH JS, LEE HG, HWANG SG, AN S, HAN YH, KIM JS. Erp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer. Oncotarget. 2015;6(35):2654–66.
28. Chichiarelli S, Guacci E, Ferraro A, Grillo C, Altieri F, Cocchiola R, Arcangeli V, Turano C, Eufemi M. Role of Erp57 in the signaling and transcriptional
activity of STAT3 in a melanoma cell line. Arch Biochem Biophys. 2010; 494(2):178–83.
29. Kozlov G, Maatantan P, Schrag JD, Pollock S, Cygler M, Nagar B, Thomas DY, Gehring K. Crystal structure of the bb' domains of the protein disulfide isomerase Erp57. Structure. 2006; 14(8):1311–9.
30. Bourdi M, Demady D, Martin JL, Jabbour SK, Martin BM, George JW, Pohl LR. Protein disulfide isomerase (PDI) and its role in placental physiology and function. Placenta. 2014; 35:293–300.
31. Liu Y, Guo Y, Song N, Fan Y, Li K, Teng X, Guo Q, Ding Z. Proteomic pattern changes associated with obesity-induced androgenesis. Andrology. 2015;3(2):247–59.
32. Adikesavan AK, Unni E, Jaiswal AK. STAT3: a versatile transcription factor that regulates a variety of human diseases. Cancer Treat Rev. 2008;34(6):488–95.
33. Li J, Shi W, Yu Q. The role of STAT3 in cancer cell survival. Cell Biol Int. 2010;34(10):996–1002.
34. Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of Stat3 in cancer. Sci Rep. 2015;5:17663.
35. Ramirez-Rangel I, Brao-Valdes I, Vazquez-Macias A, Carretero-Ortega J, Reyes-Cruz G, Vazquez-Prado J. Regulation of mTORC1 complex assembly and signaling by GRP58/ERp57. Mol Cell Biol. 2011;31(8):1657–71.
36. Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018;37(30):4094–109.
37. Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, Zhou Z, Zhang W, Qin L, Huang G. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018;37(30):4094–109.
38. Duchiange N, Pidoux J, Camus E, Sauvaget D. Alternative splicing in the human interleukin enhancer binding factor 3 (ILF3) gene. Gene. 2002;261(2):345–53.
39. Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamakawa K, Kita A, Nakahara T, et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun. 2011;425(4):711–6.
40. Pfeifer I, Elsbry R, Fernandez M, Faria PA, Nussenzveig DR, Lossos IS, Fontoura BM, Martin WD, Barber GN. NFAR-1 and NFAR-2: low-affinity translation and are required for efficient host defense. Proc Natl Acad Sci U S A. 2008;105(11):4173–8.
41. Shi L, Qiu D, Zhao G, Corteshe B, Lees-Miller S, Reeves WH, Kao PN. Dynamic binding of Ku80, Ku70 and NF90 to the IL-2 promoter in vivo. Mol Cell Biol. 2002;22(2):772–83.

Publisher’s Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.